This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
by Zacks Equity Research
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
by Zacks Equity Research
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 5.56% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 210.2% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Immuneering Corporation (IMRX) a New Buy Stock
by Zacks Equity Research
Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
by Zacks Equity Research
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -14.71% and 9.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is a Surprise Coming for Immuneering (IMRX) This Earnings Season?
by Zacks Equity Research
Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Immuneering (IMRX) Ahead of Earnings?
by Zacks Equity Research
Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.